SP
BravenNow
Phibro Animal Health (PAHC) director sells $1.1 million in stock
| USA | economy | ✓ Verified - investing.com

Phibro Animal Health (PAHC) director sells $1.1 million in stock

#Phibro Animal Health #PAHC stock #Insider trading #Director sales #52-week high #Rule 10b5-1 #Q2 2026 earnings #Stock valuation

📌 Key Takeaways

  • Director Jack Bendheim and BFI Co. sold $1.1 million in PAHC stock
  • The sales occurred over three days at prices ranging from $51.27 to $54.35
  • The transactions were part of a pre-arranged trading plan from May 2025
  • PAHC recently reported stronger-than-expected Q2 2026 results
  • The stock is trading near its 52-week high with a P/E ratio of 24.15

📖 Full Retelling

Jack Bendheim, a director of Phibro Animal Health, and BFI Co., LLC, a ten percent owner, sold $1.1 million worth of the company's Class A Common Stock on NASDAQ between February 24 and February 26, 2026, as the stock trades near its 52-week high with analysts considering it potentially overvalued. The transactions involved a total of 20,120 shares sold at prices ranging from $51.2679 to $54.2826, with sales executed according to a pre-arranged Rule 10b5-1 trading plan adopted on May 30, 2025. The sales were spread across three days, with the highest prices achieved on the final day of trading, suggesting the stock was appreciating during the sales period. Despite these insider sales, Phibro Animal Health has recently demonstrated strong financial performance, with Q2 2026 earnings per share reaching $0.87, significantly exceeding analyst expectations of $0.68 by 27.94%. The company's revenue also surpassed forecasts, reaching $373.9 million compared to the anticipated $355.24 million.

🏷️ Themes

Insider Trading, Stock Market Performance, Corporate Finance

📚 Related People & Topics

Insider trading

Insider trading

Trading using nonpublic information

# Insider Trading **Insider trading** is the trading of a public company's stock or other securities (such as bonds or stock options) based on **material, nonpublic information** about the company. While the practice is common, its legality is subject to complex regulations that vary significantly ...

View Profile → Wikipedia ↗

Stock valuation

Method of calculating theoretical values of companies and their stocks

Stock valuation is the method of calculating theoretical values of companies and their stocks. The main use of these methods is to predict future market prices, or more generally, potential market prices, and thus to profit from price movement – stocks that are judged undervalued (with respect to th...

View Profile → Wikipedia ↗

Phibro Animal Health

Phibro Animal Health Corporation is an American animal health and mineral nutrition company. Its products include antibacterials, anticoccidials, anthelmintics, as well as animal nutrition and vaccines for livestock. The company operates through three segments Mineral Nutrition, Performance Material...

View Profile → Wikipedia ↗

Entity Intersection Graph

Connections for Insider trading:

🌐 SEC filing 5 shared
👤 New York Stock Exchange 4 shared
👤 Rachel Haurwitz 3 shared
🌐 ZWS 2 shared
🌐 Biopharmaceutical 2 shared
View full profile
Original Source
try{ var _=i o; . if(!_||_&&typeof _==="object"&&_.expiry Netflix declines to match Paramount Skydance bid for Warner Bros Dorsey’s Block slashes workforce 40% to embrace AI-native future, shares gain S&P 500, Nasdaq end in the red as Nvidia drags chip stocks lower Gold prices mixed as U.S.-Iran nuclear talks end after ’significant progress’ (South Africa Philippines Nigeria) Phibro Animal Health director sells $1.1 million in stock By Investing.com Insider Trading Published 02/26/2026, 07:31 PM Phibro Animal Health director sells $1.1 million in stock 0 PAHC 3.01% Director Jack Bendheim and BFI Co., LLC, a ten percent owner, reported selling $1.1 million worth of Phibro Animal Health Corp NASDAQ:PAHC Class A Common Stock between February 24 and February 26, 2026. The sales come as the stock trades near its 52-week high of $56.30, with shares currently at $54.70. According to InvestingPro analysis, the stock appears overvalued at current levels, with a P/E ratio of 24.15 and trading at a high Price/Book multiple of 6.48. The sales, executed by BFI Co., LLC, involved a total of 20,120 shares sold at prices ranging from $51.2679 to $54.2826. These sales were executed according to a pre-arranged Rule 10b5-1 trading plan adopted on May 30, 2025. Specifically, on February 24, 2026, 5,889 shares were sold at a weighted average price of $51.2679, with individual prices ranging from $50.755 to $51.75, and 1,151 shares were sold at a weighted average price of $51.8799, in a range of $51.80 to $52.065. On February 25, 2026, 7,040 shares were sold at an average price of $51.7104, with prices varying from $51.275 to $52.27. Finally, on February 26, 2026, 6,329 shares were sold at an average price of $53.6690, in a range of $53.21 to $54.10, and 711 shares were sold at a weighted average price of $54.2826, with prices between $54.27 and $54.355. InvestingPro subscribers have access to 14 additional exclusive tips about PAHC, plus comprehensive Pro Research Reports covering 1,400...
Read full article at source

Source

investing.com

More from USA

News from Other Countries

🇬🇧 United Kingdom

🇺🇦 Ukraine